- Home
- RYTM vs KRYS Comparison
RYTM vs KRYS Comparison
Compare RYTM & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYTM
- KRYS
- Stock Information
- Founded
- RYTM 2008
- KRYS 2015
- Country
- RYTM United States
- KRYS United States
- Employees
- RYTM N/A
- KRYS N/A
- Industry
- RYTM Biotechnology: Pharmaceutical Preparations
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RYTM Health Care
- KRYS Health Care
- Exchange
- RYTM Nasdaq
- KRYS Nasdaq
- Market Cap
- RYTM 4.3B
- KRYS 3.8B
- IPO Year
- RYTM 2017
- KRYS 2017
- Fundamental
- Price
- RYTM $66.36
- KRYS $140.51
- Analyst Decision
- RYTM Strong Buy
- KRYS Strong Buy
- Analyst Count
- RYTM 12
- KRYS 9
- Target Price
- RYTM $77.50
- KRYS $208.78
- AVG Volume (30 Days)
- RYTM 585.3K
- KRYS 383.3K
- Earning Date
- RYTM 08-05-2025
- KRYS 08-04-2025
- Dividend Yield
- RYTM N/A
- KRYS N/A
- EPS Growth
- RYTM N/A
- KRYS 109.01
- EPS
- RYTM N/A
- KRYS 4.16
- Revenue
- RYTM $136,863,000.00
- KRYS $333,448,000.00
- Revenue This Year
- RYTM $37.56
- KRYS $44.05
- Revenue Next Year
- RYTM $74.99
- KRYS $46.15
- P/E Ratio
- RYTM N/A
- KRYS $33.49
- Revenue Growth
- RYTM 48.88
- KRYS 247.53
- 52 Week Low
- RYTM $40.46
- KRYS $122.80
- 52 Week High
- RYTM $69.89
- KRYS $219.34
- Technical
- Relative Strength Index (RSI)
- RYTM 60.43
- KRYS 54.07
- Support Level
- RYTM $60.80
- KRYS $135.86
- Resistance Level
- RYTM $64.00
- KRYS $143.44
- Average True Range (ATR)
- RYTM 2.05
- KRYS 5.39
- MACD
- RYTM 0.17
- KRYS 0.96
- Stochastic Oscillator
- RYTM 100.00
- KRYS 66.65
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.